Compounds > dithiopyr
Page last updated: 2024-11-06

dithiopyr

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dithiopyr: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91757
CHEMBL ID1902931
CHEBI ID81987
SCHEMBL ID55203
MeSH IDM0194976

Synonyms (37)

Synonym
dithiopyr
brn 4272584
mon 7200
3,5-pyridinedicarbothioic acid, 2-(difluoromethyl)-4-(2-methylpropyl)-6-(trifluoromethyl)-, s,s-dimethyl ester
dithiopyr [iso]
mon 15100
dimension
NCGC00163911-01
s3,s5-dimethyl 2-(difluoromethyl)-4-isobutyl-6-(trifluoromethyl)pyridine-3,5-dicarbothioate
97886-45-8
NCGC00163911-02
3-s,5-s-dimethyl 2-(difluoromethyl)-4-(2-methylpropyl)-6-(trifluoromethyl)pyridine-3,5-dicarbothioate
NCGC00163911-03
C18826
dtxcid7012379
dtxsid9032379 ,
NCGC00255048-01
cas-97886-45-8
tox21_301150
unii-2txf17hav1
2txf17hav1 ,
hsdb 8446
FT-0630996
mon-15100
AKOS015902531
s,s'-dimethyl 2-difluoromethyl-4-isobutyl-6-trifluoromethylpyridine-3,5-dicarbothioate
s,s'-dimethyl 2-(difluoromethyl)-4-(2-methylpropyl)-6-(trifluoromethyl)-3,5-pyridinedicarbothioate
mon-7200
dithiopyr [mi]
2-(difluoromethyl)-4-(2-methylpropyl)-6-(trifluoromethyl)-3,5-pyridinedicarbothioic acid s3,s5-dimethyl ester
s,s-dimethyl 2-(difluoromethyl)-4-isobutyl-6-trifluoromethyl-3,5-pyridinedicarbothioate
SCHEMBL55203
CHEBI:81987 ,
CHEMBL1902931
s,s-dimethyl 2-(difluoromethyl)-4-isobutyl-6-(trifluoromethyl)pyridine-3,5-bis(carbothioate)
Q5283665
DB15230
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
thioesterA compound of general formula RC(=O)SR'. Compare with thionoester, RC(=S)OR'.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
pregnane X receptorRattus norvegicus (Norway rat)Potency31.62280.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency54.15040.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency68.17130.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency37.05350.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency68.17130.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency48.26160.001022.650876.6163AID1224839
progesterone receptorHomo sapiens (human)Potency30.45100.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency54.61180.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency36.73210.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.63800.000817.505159.3239AID1159527; AID1159531; AID588544
farnesoid X nuclear receptorHomo sapiens (human)Potency54.61180.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency9.47580.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency42.13900.000229.305416,493.5996AID743069; AID743075; AID743078
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.67280.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency61.27540.023723.228263.5986AID743222; AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency76.48950.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.17130.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency27.13950.001628.015177.1139AID1224895
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.17130.000323.4451159.6830AID743065; AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (42.86)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.51 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index85.01 (26.88)
Search Engine Supply Index3.91 (0.95)

This Compound (34.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nadp
[no description available]		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Diseases, Occupational
[description not available]		01.9710